Retatrutide

Metabolic Research Peptides · 20mg vial

Retatrutide

Message for Price

Retatrutide (LY3437943) is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents one of the most advanced metabolic research peptides currently being studied, showing significant results in clinical weight management trials.

Research has demonstrated Retatrutide's ability to improve insulin sensitivity, regulate appetite signalling, and support meaningful reductions in body weight. As a triple receptor agonist, it combines the complementary mechanisms of GLP-1 (satiety), GIP (metabolic enhancement), and glucagon (energy expenditure) in a single compound.

Composition & Purity

Retatrutide (LY3437943), Lyophilized powder

Research applications: Metabolic optimization research, Appetite and satiety signalling studies, Insulin sensitivity models, Extended weight management protocols
Not intended for: Human therapeutic use, Veterinary use
Qty
1

For research purposes only

Compound: Retatrutide (LY3437943) — GLP-1/GIP/Glucagon triple agonist

Concentration: 20mg lyophilized powder

Purity: ≥99.9% (HPLC verified)

Storage: Refrigerate at 2–8°C. Protect from light. Reconstitute with bacteriostatic water prior to use.

COA: Available on request.

Size
20mg vial
Weight
20mg